Dr. David V. Sheehan MD

Panic anxiety: diagnosis, etiology, and treatment.

Raj, A., Sheehan, D. V.

Snorting benzodiazepines.

Sheehan, M. F., Sheehan, D. V., Torres, A., Coppola, A., Francis, E.

Umbilical concretion.

Sheehan, D.,Hussain, S.,Vijayaraghavan, G.

The Ontario Mother and Infant Survey: breastfeeding outcomes.

Sheehan, D., Krueger, P., Watt, S., Sword, W., Bridle, B.

Costs of postpartum care: examining associations from the Ontario mother and infant survey.

Roberts, J., Sword, W., Watt, S., Gafni, A., Krueger, P., Sheehan, D., Soon-Lee, K.

Voriconazole susceptibilities of dermatophyte isolates obtained from a worldwide tinea capitis clinical trial.

Ghannoum, M., Isham, N., Sheehan, D.

Multivariate analysis of changes in panic frequency counts.

Overall, J. E., Sheehan, D. V.

SIBAT-A Computerized Assessment Tool for Suicide Ideation and Behavior: Development and Psychometric Properties.

Larry Alphs, Dong-Jing Fu, David Williamson, Carol Jamieson, John Greist, Magdalena Harrington, Jean-Pierre Lindenmayer, Cheryl McCullumsmith, David V Sheehan, Richard C Shelton, Paul Wicks, Carla M Canuso

Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale.

Karen S. Yee, Robin Pokrzywinski, Asha Hareendran, Shannon Shaffer, David V. Sheehan

Pilot Mental Health Survey, Nepal: Lessons Learned for Survey Design and Instrumentation.

Sushma Dahal, Meghnath Dhimal, Sagun Ballav Pant, Pawan Sharma, Kedar Marahatta, Nagendra P. Luitel, Suraj Shakya, Sweta Labh, Saroj Prasad Ojha, Anjani Kumar Jha, David V. Sheehan

THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial

Anthony L. Vaccarino, Amir H Kalali, Pierre Blier, Susan Gilbert Evans, Nina Engelhardt, Jane A. Foster, Benicio N. Frey, John H. Greist, Kenneth A. Kobak, Raymond W. Lam, Glenda MacQueen, Roumen Milev, Daniel J. Müller, Sagar V. Parikh, Franca M. Placenza, Sakina J. Rizvi, Susan Rotzinger, David V. Sheehan, Terrence Sills, Claudio N. Soares, Gustavo Turecki, Rudolph Uher, Janet B. W. Williams, Sidney H. Kennedy, Kenneth R. Evans

THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial

Anthony L. Vaccarino, Amir H Kalali, Pierre Blier, Susan Gilbert Evans, Nina Engelhardt, Jane A. Foster, Benicio N. Frey, John H. Greist, Kenneth A. Kobak, Raymond W. Lam, Glenda MacQueen, Roumen Milev, Daniel J. Müller, Sagar V. Parikh, Franca M. Placenza, Sakina J. Rizvi, Susan Rotzinger, David V. Sheehan, Terrence Sills, Claudio N. Soares, Gustavo Turecki, Rudolph Uher, Janet B. W. Williams, Sidney H. Kennedy, Kenneth R. Evans

A population-based analysis of suicidality and its correlates: findings from the National Mental Health Survey of India, 2015-16.

Senthil Amudhan, Gopalkrishna Gururaj, Mathew Varghese, Vivek Benegal, Girish N Rao, David V. Sheehan, Arun M Kokane, Bir Singh Chavan, Pronob Kumar Dalal, Daya Ram, Kangkan Pathak, Raj Kumar Lenin Singh, Lokesh Kumar Singh, Pradeep Sharma, Pradeep Kumar Saha, Chellamuthu Ramasubramanian, Ritambhara Y Mehta, Theerthankara Meethal Shibukumar

Effects of Lisdexamfetamine Dimesylate on Functional Impairment Measured on the Sheehan Disability Scale in Adults With Moderate-to-severe Binge Eating Disorder: Results from Two Randomized, Placebo-controlled Trials.

David V. Sheehan, Maria Gasior, Susan L. McElroy, Jana Radewonuk, Barry K. Herman, James I. Hudson

Restoring function in major depressive disorder: A systematic review.

David V. Sheehan, Kazuyuki Nakagome, Yuko Asami, Elizabeth Pappadopulos, Matthieu Boucher

The effect of vortioxetine on overall patient functioning in patients with major depressive disorder

Ioana Florea, Henrik Loft, Natalya Danchenko, B. Rive, M. Brignone, Elizabeth Merikle, Paula L. Jacobsen, David V. Sheehan

Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial

Suresh Durgam, Carl Gommoll, Giovanna Forero, Rene Nunez, Xiongwen Tang, Maju Mathews, David V. Sheehan

Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment

Richard H. Weisler, Ai Ota, Kana Tsuneyoshi, Pamela Perry, Emmanuelle Weiller, Ross A. Baker, David V. Sheehan

The Depression Inventory Development Workgroup: A Collaborative, Empirically Driven Initiative to Develop a New Assessment Tool for Major Depressive Disorder.

Anthony L. Vaccarino, Kenneth R. Evans, Amir H Kalali, Sidney H. Kennedy, Nina Engelhardt, Benicio N. Frey, John H. Greist, Kenneth A. Kobak, Raymond W. Lam, Glenda MacQueen, Roumen Milev, Franca M. Placenza, Arun Ravindran, David V. Sheehan, Terrence Sills, Janet B. W. Williams

Assessing the Reliability and Validity of the Sheehan Irritability Scale in Patients With Major Depressive Disorder

Sajjad A. Khan, Dennis A. Revicki, Mariam Hassan, Julie C. Locklear, Lisa Aronson Friedman, Sally Mannix, Raj Tummala, Dunbar Geoffrey Charles, Hans Eriksson, David V. Sheehan

Importance of Restoring Function in Patients With Major Depressive Disorder.

David V. Sheehan

A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder

Tamás Ágh, Gábor Kovács, Dylan Supina, Manjiri Pawaskar, Barry K. Herman, Zoltán Vokó, David V. Sheehan

Content validity of the Sheehan Irritability Scale in patients with major depressive disorder.

Sally Mannix, Mariam Hassan, Raj Tummala, Julie C. Locklear, Dennis A. Revicki, Sajjad Wali Khan, Dunbar Geoffrey Charles, Hans Eriksson, David V. Sheehan

Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors.

David V. Sheehan, Michele Mancini, Jianing Wang, Lovisa Berggren, Haijun Cao, Héctor José Dueñas, Li Yue

Longitudinal Modeling The Effect Of Lisdexamfetamine Dimesylate And Changes In Binge Eating Frequency On Disability In Patients With Binge Eating Disorder.

Manjiri Pawaskar, Z Vokó, Tamás Ágh, David V. Sheehan, SL McElroy, Jana Radewonuk, G. Merész, Barry K. Herman, Maria Gasior

The Psychological and Medical Factors Associated With Untreated Binge Eating Disorder

David V. Sheehan, Barry K. Herman

Is a count of suicidal ideation and behavior events useful in assessing global severity of suicidality? A case study

Jennifer M Giddens, David V. Sheehan

How the Timing of a Patient's Self-ratings of Suicidality and the Relationship to the Recipient Affect Patient Responses: A Case Study.

Jennifer M Giddens, David V. Sheehan

Is There Value in Asking the Question "Do you think you would be better off dead?" in Assessing Suicidality? A Case Study.

Jennifer M Giddens, David V. Sheehan

The complexity of assessing overall severity of suicidality: a case study.

Jennifer M Giddens, David V. Sheehan

Status Update on the Sheehan-Suicidality Tracking Scale (S-STS) 2014.

David V. Sheehan, Jennifer M Giddens, Ivan Sascha Sheehan

The Columbia-Suicide Severity Rating Scale (C-SSRS): Has the "Gold Standard" Become a Liability?

Jennifer M Giddens, Kathy Harnett Sheehan, David V. Sheehan

Current assessment and classification of suicidal phenomena using the FDA 2012 Draft Guidance Document on Suicide Assessment: a critical review

David V. Sheehan, Jennifer M Giddens, Kathy Harnett Sheehan

Comparative Validation of the S-STS, the ISST-Plus, and the C-SSRS for Assessing the Suicidal Thinking and Behavior FDA 2012 Suicidality Categories

David V. Sheehan, Larry Alphs, Lian Mao, Qin Li, Roberta S. May, Emily H. Bruer, Cheryl B. McCullumsmith, Christopher R Gray, Xiaohua Li, David J. Williamson

Linguistic Validation of the Pediatric Versions of the Sheehan Suicidality Tracking Scale (S-STS).

Darlene M. Amado, Darlene A. Beamon, David V. Sheehan

Comparative Validation of the S-STS, the ISST-Plus, and the C-SSRS for Assessing the Suicidal Thinking and Behavior FDA 2012 Suicidality Categories

David V. Sheehan, Larry Alphs, Lian Mao, Qin Li, Roberta S. May, Emily H. Bruer, Cheryl B. McCullumsmith, Christopher R Gray, Xiaohua Li, David J. Williamson

Do the Five Combinations of Suicidal Ideation in the FDA 2012 Draft Guidance Document and the C-SSRS Adequately Cover All Suicidal Ideation Combinations in Practice? A Case Study.

Jennifer M Giddens, David V. Sheehan

Simple Measures of Hopelessness and Impulsivity are Associated with Acute Suicidal Ideation and Attempts in Patients in Psychiatric Crisis.

Cheryl B. McCullumsmith, David J. Williamson, Roberta S. May, Emily H. Bruer, David V. Sheehan, Larry Alphs

Simple Measures of Hopelessness and Impulsivity are Associated with Acute Suicidal Ideation and Attempts in Patients in Psychiatric Crisis.

Cheryl B. McCullumsmith, David J. Williamson, Roberta S. May, Emily H. Bruer, David V. Sheehan, Larry Alphs

A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.

Angelo Sambunaris, Anjana Bose, Carl Gommoll, Changzheng Chen, William M. Greenberg, David V. Sheehan

A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder.

Trisha Suppes, Susan L. McElroy, David V. Sheehan, Rosario B. Hidalgo, Victoria E. Cosgrove, Iola S. Gwizdowski, Natalie S. Feldman

Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study

David V. Sheehan, Henrik Svedsater, Julie C. Locklear, Hans Eriksson

Relationship between major depressive disorder and associated painful physical symptoms: analysis of data from two pooled placebo-controlled, randomized studies of duloxetine.

Michael J. Robinson, David V. Sheehan, Paula J. Gaynor, Lauren B. Marangell, Yoko Tanaka, Sarah Lipsius, Fumihiro Ohara, Chihiro Namiki

Sheehan Suicidality Tracking Scale (S-STS): reliability, convergent and discriminative validity in young Italian adults.

Antonio Preti, David V. Sheehan, Vladimir Coric, Marco Distinto, Mirko Pitanti, Irene Vacca, Alessandra Siddi, Carmelo Masala, Donatella Rita Petretto

Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring bipolar disorder and anxiety disorder.

J.S. Seo, K. Jamieson, Victoria E. Cosgrove, I.S. Gwizdowski, H. Yang, David V. Sheehan, Susan L. McElroy, Trisha Suppes

Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient

David V. Sheehan, K. Harnett-Sheehan, Rosario B. Hidalgo, J. Janavs, Susan L. McElroy, Darlene M. Amado, Trisha Suppes

Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial

Leszek Bidzan, Atul R. Mahableshwarkar, Paula L. Jacobsen, Mingjin Yan, David V. Sheehan

Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States

Anthony J. Rothschild, Atul R. Mahableshwarkar, Paula L. Jacobsen, Mingjin Yan, David V. Sheehan

Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies.

Michele Mancini, David V. Sheehan, Koen Demyttenaere, Mario Amore, Walter Deberdt, Deborah Quail, Doron Sagman

Humanistic and economic burden of generalized anxiety disorder in North America and Europe

Dennis A. Revicki, Karin Travers, Kathleen W. Wyrwich, Henrik Svedsater, Julie C. Locklear, Maria Stoeckl Mattera, David V. Sheehan, Stuart Montgomery

Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate.

David V. Sheehan, Julie C. Locklear, Henrik Svedsater, Catherine Datto

Generalized anxiety disorder.

Rosario B. Hidalgo, David V. Sheehan

Echinocandins: are they all the same?

Mukherjee PK, Sheehan D, Puzniak L, Schlamm H, Ghannoum MA

Unusual complication after left-lobe liver biopsy for diffuse liver disease: severe bleeding from the superior epigastric artery.

Gopal R. Vijayaraghavan, David Sheehan, Larry Zheng, Sarwat Hussain, Joseph T. Ferrucci

Patients with obsessive-compulsive disorder vs depression have comparable health care costs: A retrospective claims analysis of Florida Medicaid enrollees

Cheryl S. Hankin, Lorrin M. Koran, David V. Sheehan, Eric Hollander, Larry Culpepper, Donald W. Black, John Knispel, Jeffrey Dunn, Darin D. Dougherty, Amy Bronstone, Zhaohui Wang

Assessment of Anxiety in Clinical Trials with Depressed Patients Using the Hamilton Depression Rating Scale.

C Goldberger, J D Guelfi, David V. Sheehan

Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.

Maurizio Fava, Gregory M. Asnis, Ram K. Shrivastava, Bruce Lydiard, Bijan Bastani, David V. Sheehan, Thomas Roth

The use of research measures in adult clinical practice.

Busner J, Kaplan Sl, Greco N th, David V. Sheehan

Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine.

David V. Sheehan, Pratap Chokka, Renee E. Granger, Richard Walton, Joel Raskin, Doron Sagman

Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs.

Tami L. Mark, Vijay N. Joish, Joel W. Hay, David V. Sheehan, Stephen S. Johnston, Zhun Cao

Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale

David V. Sheehan, K. Harnett-Sheehan, Melissa E. Spann, Harry F. Thompson, Apurva Prakash

Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement.

Roger E. Meyer, Carl Salzman, Eric A. Youngstrom, Paula J. Clayton, Frederick K. Goodwin, J. John Mann, Larry Alphs, Karl Broich, Wayne K. Goodman, John F. Greden, Herbert Y. Meltzer, Sharon-Lise T. Normand, Kelly Posner, David Shaffer, Maria A. Oquendo, Barbara Stanley, Madhukar H. Trivedi, Gustavo Turecki, Charles M. Beasley, Annette L. Beautrais, Jeffrey A. Bridge, Gregory K. Brown, Dennis A. Revicki, Neal D. Ryan, David V. Sheehan

Expenditures associated with dose titration at initiation of therapy in patients with major depressive disorder: a retrospective analysis of a large managed care claims database.

Fabian Camacho, Meg C. Kong, David V. Sheehan, Rajesh Balkrishnan

Suicidality and risk of suicide - Definition, drug safety concerns, and a necessary target for drug development: A brief report

Roger E. Meyer, Carl Salzman, Eric A. Youngstrom, Paula J. Clayton, Frederick K. Goodwin, J. John Mann, Larry Alphs, Karl Broich, Wayne K. Goodman, John F. Greden, Herbert Y. Meltzer, Sharon-Lise T. Normand, Kelly Posner, David Shaffer, Maria A. Oquendo, Barbara Stanley, Madhukar H. Trivedi, Gustavo Turecki, Charles M. Beasley, Annette L. Beautrais, Jeffrey A. Bridge, Gregory K. Brown, Dennis A. Revicki, Neal D. Ryan, David V. Sheehan

Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID).

David V. Sheehan, Kathy Harnett Sheehan, R. Douglas Shytle, J. Janavs, Yvonne Bannon, Jamison E. Rogers, Karen M. Milo, Saundra Stock, Berney J. Wilkinson

Benzodiazepines risk, abuse, and dependence: a tsunami in a tea cup.

Rosario B. Hidalgo, David V. Sheehan

Adequacy of Pharmacotherapy Among Medicaid-Enrolled Patients Newly Diagnosed with Obsessive-Compulsive Disorder

Cheryl S. Hankin, Lorrin M. Koran, Amy Bronstone, Donald W. Black, David V. Sheehan, Eric Hollander, Jeffrey Dunn, Larry Culpepper, John Knispel, Darin D. Dougherty, Zhaohui Wang

Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders.

Keming Gao, David V. Sheehan, Joseph R. Calabrese

Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder.

Maurizio Fava, Gregory M. Asnis, Ram K. Shrivastava, Bruce Lydiard, Bijan Bastani, David V. Sheehan, Thomas Roth

Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.

David V. Sheehan, Susan L. McElroy, K. Harnett-Sheehan, Paul E. Keck, J. Janavs, Jamison E. Rogers, Robert Gonzalez, Geetha Shivakumar, Trisha Suppes

Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study.

David V. Sheehan, Croft Ha, Gossen Er, Levitt Rj, Brullé C, Bouchard S, Rozova A

An evidence-based review of the clinical use of sertraline in mood and anxiety disorders

David V. Sheehan, Kunitoshi Kamijima

Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features.

David V. Sheehan, Charles B. Nemeroff, Michael E. Thase, Richard Entsuah

The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder

David V. Sheehan, Rozova A, Gossen Er, Gibertini M

Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary Results from a Multicenter Clinical Trial in Generalized Anxiety Disorder.

Vladimir Coric, Elyse Stock, Joseph Pultz, Ronald N. Marcus, David V. Sheehan

Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine.

Michael J. Owens, Stan Krulewicz, Jeffrey S. Simon, David V. Sheehan, Michael E. Thase, David J. Carpenter, Susan J Plott, Charles B. Nemeroff

The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder.

David V. Sheehan, Adam L. Meyers, Apurva Prakash, Michael J. Robinson, Ralph Swindle, James M. Russell, Craig H. Mallinckrodt

Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale.

Kathy Harnett Sheehan, David V. Sheehan

Efficacy of print advertising for a bipolar disorder study.

Sumeet Roy, Shilpa Patel, Kathy Harnett Sheehan, J. Janavs, David V. Sheehan

Differences in Medication Adherence and Healthcare Resource Utilization Patterns : Older versus Newer Antidepressant Agents in Patients with Depression and/or Anxiety Disorders

David V. Sheehan, Matthew S Keene, Michael Eaddy, Stan Krulewicz, John E. Kraus, David J. Carpenter

Perceived stress in anxiety disorders and the general population: A study of the Sheehan stress vulnerability scale

Kathryn M. Connor, Sandeep Vaishnavi, Jonathan R. T. Davidson, David V. Sheehan, K. Harnett Sheehan

An open-label study of tiagabine in panic disorder.

David V. Sheehan, Kathy Harnett Sheehan, B A Raj, J. Janavs

The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder.

David V. Sheehan, Kathy Harnett Sheehan, B A Raj

Current approaches to the pharmacologic treatment of anxiety disorders.

David V. Sheehan, Kathy Harnett Sheehan

Generic Conversion of the SSRI Market and the Impact on Branded Products.

Elisa F Cascade, Amir H Kalali, David V. Sheehan

Differences in total medical costs across the SSRIs for the treatment of depression and anxiety.

David V. Sheehan, Michael Eaddy, Manan B Shah, Robert P. Mauch

Comparing the Effects of Antidepressants: Consensus Guidelines for Evaluating Quantitative Reviews of Antidepressant Efficacy

J.A. Lieberman, Joel B. Greenhouse, Robert M. Hamer, K. Ranga Rama Krishnan, Charles B. Nemeroff, David V. Sheehan, Michael E. Thase, Martin B. Keller

Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder.

David V. Sheehan, Daniel B. Burnham, Malini K. Iyengar, Philip Perera

Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine.

David V. Sheehan, Michael Eaddy, Matthew W. Sarnes, Tejal Vishalpura, Timothy S. Regan

Depression: underdiagnosed, undertreated, underappreciated.

David V. Sheehan

The Tourette's Disorder Scale (TODS): development, reliability, and validity.

R. Douglas Shytle, Archie A. Silver, Kathy Harnett Sheehan, Berney J. Wilkinson, Mary B. Newman, Paul R. Sanberg, David V. Sheehan

Improved tolerability and increased length of therapy.

David V. Sheehan

Paroxetine Treatment of Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Study

Karl Rickels, Rocco Zaninelli, James P. McCafferty, Kevin M. Bellew, Malini K. Iyengar, David V. Sheehan

Paroxetine treatment of generalized anxiety disorder.

David V. Sheehan, Mao Cg

The management of panic disorder.

David V. Sheehan

Generalized anxiety disorder: comorbidity, comparative biology and treatment.

David J. Nutt, James C. Ballenger, David V. Sheehan, Hans-Ulrich Wittchen

Establishing the real cost of depression.

David V. Sheehan

Establishing the real cost of depression.

David V. Sheehan

The importance of adequate length of antidepressant therapy.

David V. Sheehan

Nicotinic acetylcholine receptors as targets for antidepressants.

Roland Douglas Shytle, Archie A. Silver, Ronald J. Lukas, Mary B. Newman, David V. Sheehan, Paul R. Sanberg

Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR.

Stuart Montgomery, David V. Sheehan, Paolo Meoni, Vincent Haudiquet, David Hackett

Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial

Jonathan R. T. Davidson, Kishore M. Gadde, John A. Fairbank, K. Ranga Rama Krishnan, Robert M. Califf, Cynthia Binanay, Corette B. Parker, Norma Pugh, Tyler Hartwell, Benedetto Vitiello, Louise Ritz, Joanne B. Severe, Jonathan O. Cole, Charles De Battista, P. Murali Doraiswamy, John P. Feighner, Paul E. Keck, Jeffrey E. Kelsey, Khae Ming Lin, Peter D. Londborg, Charles B. Nemeroff, Alan F. Schatzberg, David V. Sheehan, Ram K. Srivastava, L. P. Taylor, Madhukar H. Trivedi, Richard H. Weisler

Impact of formulary restrictions on the cost-effectiveness of antidepressant treatment.

David V. Sheehan, Pamela J Wright-Etter

Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine.

R. Douglas Shytle, Archie A. Silver, Kathy Harnett Sheehan, David V. Sheehan, Paul R. Sanberg

Generalized anxiety disorder: raising the expectations of treatment.

Christer Allgulander, David V. Sheehan

Have drug companies hyped social anxiety disorder to increase sales. No: Efforts to relieve human suffering deserve rewards.

David V. Sheehan

Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder

Archie A. Silver, R. Douglas Shytle, Kathy Harnett Sheehan, David V. Sheehan, Amaya E. Ramos, Paul R. Sanberg

Social anxiety disorder.

B. Ashok Raj, David V. Sheehan

Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.

David V. Sheehan

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

Karl Rickels, Mark H. Pollack, David V. Sheehan, J T Haskins

Venlafaxine Extended Release (XR) in the Treatment of Generalized Anxiety Disorder

David V. Sheehan

Introduction. New treatments for anxiety disorders: clinical approaches for successful outcomes.

David V. Sheehan

Current concepts in the treatment of panic disorder.

David V. Sheehan

Diagnostic errors of primary care screens for depression and panic disorder.

Andrew C. Leon, Laura Portera, Mark Olfson, Roger G. Kathol, Leslie Farber, Kira N. Lowell, David V. Sheehan

Physician Substance Use by Medical Specialty

Patrick H. Hughes, Carla L. Storr, Nancy A. Brandenburg, DeWitt C. Baldwin, James C. Anthony, David V. Sheehan

A diagnostic aid for detecting (DSM-IV) mental disorders in primary care ☆

Myrna M. Weissman, W. Eugene Broadhead, Mark Olfson, David V. Sheehan, Christina W. Hoven, Patricia Conolly, Bruce Fireman, Leslie Farber, Robert S. Blacklow, E S Higgins, Andrew C. Leon

DSM-IH-R Psychotic Disorders: procedural validity of the Mini International Neuropsychiatric Interview (MINI). Concordance and causes for discordance with the CIDI.

P. Amorim, Yves Lecrubier, E Weiller, T. Hergueta, David V. Sheehan

The Mini-International Neuropsychiatric Interview (M.I.N.I.) : The development and validation of a Structured Diagnostic Psychiatric Interview for DSM-IV and ICD-10

David V. Sheehan, Yves Lecrubier, Kathy Harnett Sheehan, P. Amorim, J. Janavs, Emmanuelle Weiller, T. Hergueta, Ross A. Baker, Dunbar Geoffrey Charles

Mental disorders and disability among patients in a primary care group practice.

Mark Olfson, Bruce Fireman, Myrna M. Weissman, Andrew C. Leon, David V. Sheehan, Roger G. Kathol, Christina W. Hoven, Leslie Farber

False Positive Results: A Challenge for Psychiatric Screening in Primary Care

Andrew C. Leon, Laura Portera, Mark Olfson, Myrna M. Weissman, Roger G. Kathol, Leslie Farber, David V. Sheehan, Andreas M. Pleil

Assessing Psychiatric Impairment in Primary Care with the Sheehan Disability Scale

Andrew C. Leon, Mark Olfson, Laura Portera, Leslie Farber, David V. Sheehan

Psychotic symptoms in primary care.

Mark Olfson, Myrna M. Weissman, Andrew C. Leon, Leslie Farber, David V. Sheehan

suicidal ideation in primary care

Mark Olfson, Myrna M. Weissman, Andrew C. Leon, David V. Sheehan, Leslie Farber

The measurement of disability.

David V. Sheehan, K. Harnett-Sheehan, B A Raj

Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics

David V. Sheehan, Ashok Raj, K. Harnett-Sheehan, Jocelyn Dorotheo, M. Sheehan, Rajeev Trehan, Edson Knapp, Ann M Swiontek, Bernard S Coleman

Evaluation of screens for mental disorders in primary care: methodological issues.

Andrew C. Leon, Mark Olfson, Myrna M. Weissman, Laura Portera, David V. Sheehan

The role of SSRIs in panic disorder.

David V. Sheehan, K. Harnett-Sheehan

Occurrence of the Cys311 DRD2 variant in a pedigree multiply affected with panic disorder

Fiona Crawford, Jonathan Hoyne, Patricia Diaz, Aaron Osborne, Jocelyn Dorotheo, David V. Sheehan, Michael Mullan

Single ion gas chromatographic/mass spectroscopic quantitative analysis of environmental CO2 in agoraphobic environments

Stephen Cox, Jeff Lawrence, David V. Sheehan

Serotonin in panic disorder and social phobia.

David V. Sheehan, B A Raj, R. R. Trehan, E. Knapp

The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study.

D V Sheehan, A B Raj, K Harnett-Sheehan, S Soto, E Knapp

Rigidity, sensitivity and quality of attachment: the role of maternal rigidity in the early socio-emotional development of premature infants.

P R Butcher, A F Kalverboer, R B Minderaa, E F van Doormaal, Y ten Wolde

Resident physician substance use, by specialty

Patrick H. Hughes, DeWitt C. Baldwin, David V. Sheehan, Scott E. Conard, Carla L. Storr

Prevalence of substance use among US physicians.

Patrick H. Hughes, Nancy A. Brandenburg, DeWitt C. Baldwin, Carla L. Storr, Kristine M Williams, James C. Anthony, David V. Sheehan

Patterns of substance use in the medical profession.

Patrick H. Hughes, Carla L. Storr, Baldwin Dc, Kristine M Williams, Scott E. Conard, David V. Sheehan

Relations among stressors, strains, and substance use among resident physicians.

Steve M. Jex, Patrick H. Hughes, Carla L. Storr, Scott E. Conard, DeWitt C. Baldwin, David V. Sheehan

The effect of paroxetine on anxiety and agitation associated with depression.

David V. Sheehan, Dunbar Geoffrey Charles, Fuell Dl

Behavioral consequences of job-related stress among resident physicians: the mediating role of psychological strain.

Steve M. Jex, Patrick H. Hughes, Carla L. Storr, DeWitt C. Baldwin, Scott E. Conard, David V. Sheehan

Substance use among senior medical students. A survey of 23 medical schools.

DeWitt C. Baldwin, Patrick H. Hughes, Scott E. Conard, Carla L. Storr, David V. Sheehan

Resident physician substance use in the United States.

Patrick H. Hughes, Conard S, DeWitt C. Baldwin, Carla L. Storr, David V. Sheehan

Zinc abuse--an unsuspected cause of sideroblastic anemia.

Forman WB, Sheehan D, Cappelli S, Coffman B

Is buspirone effective for panic disorder

David V. Sheehan, Ashok Raj, Kathy Harnett Sheehan, Sonia Soto

A pilot study of medical student 'abuse'. Student perceptions of mistreatment and misconduct in medical school.

K. Harnett Sheehan, David V. Sheehan, Kim White, Alan I. Leibowitz, DeWitt C. Baldwin

Etiology of dental anxiety: psychological trauma or CNS chemical imbalance?

Weiner Aa, David V. Sheehan

A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression.

Deborah Roth, Jeffrey Mattes, K. Harnett Sheehan, David V. Sheehan

Mitral valve prolapse and panic disorder.

Ashok Raj, David V. Sheehan

Cocaine use by senior medical students.

Conard S, Patrick H. Hughes, Baldwin Dc, Achenbach Ke, David V. Sheehan

Substance use by fourth-year students at 13 U.S. medical schools.

Conard S, Patrick H. Hughes, Baldwin Dc, Achenbach Ke, David V. Sheehan

Differentiating anxiety-panic disorders from psychologic dental anxiety.

Weiner Aa, David V. Sheehan

The potential role of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder.

JP Zak, Jr Ja Miller, David V. Sheehan, BS Fanous

Panic disorder: the potential role of serotonin reuptake inhibitors.

David V. Sheehan, JP Zak, Miller Ja, BS Fanous

The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report.

David V. Sheehan, Ashok Raj, Sheehan Kh, Sonia Soto

Substance use and abuse among senior medical students in 23 medical schools.

DeWitt C. Baldwin, Scott E. Conard, Patrick H. Hughes, Achenbach Ke, David V. Sheehan

Substance use and the resident physician: a national study.

Scott E. Conard, Patrick H. Hughes, Baldwin Dc, Achenbach Ke, David V. Sheehan

Urinary catecholamine metabolite and tribulin output during lactate infusion.

Angela Clow, Vivette Glover, M. W. Weg, P. L. Walker, David V. Sheehan, Daniel B. Carr, M. Sandler

Benzodiazepines in panic disorder and agoraphobia.

David V. Sheehan

Recent developments in the treatment of panic disorder.

David V. Sheehan, Sonia Soto

Medical evaluation of panic attacks.

Ashok Raj, David V. Sheehan

Suriclone for generalized anxiety disorder: an escalating multiple-dose, safety, tolerance, and efficacy study.

William E. Falk, Jerrold F. Rosenbaum, David V. Sheehan, Claycomb Jb, Clarke J

Tricyclic antidepressants in the treatment of panic and anxiety disorders

David V. Sheehan

A case of bupropion-induced seizure.

David V. Sheehan, John B. Welch, Scott M. Fishman

Immunological response to stress in agoraphobia and panic attacks

Owen S. Surman, John M. Williams, David V. Sheehan, terence B. Strom, Kenneth J. Jones, James H. Coleman

A three-year follow-up of hypnosis and restricted environmental stimulation therapy for smoking.

Arreed Barabasz, Lee Baer, David V. Sheehan, Marianne Barabasz

A combination drug treatment for acute common migraine.

Eugene Uzogara, David V. Sheehan, Theo C. Manschreck, Kenneth J. Jones

Dental anxiety--the development of a measurement model.

A. A. Weiner, David V. Sheehan, K. J. Jones

Vasopressin response to lactate infusion in normals and patients with panic disorder.

Daniel B. Carr, Scott M. Fishman, N. W. Kasting, David V. Sheehan

Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy.

Daniel B. Carr, David V. Sheehan, Owen S. Surman, James H. Coleman, David J. Greenblatt, G R Heninger, Kenneth J. Jones, P H Levine, W D Watkins

The prevalence of mitral valve prolapse in patients with panic disorders.

Richard R. Liberthson, David V. Sheehan, Mary Etta King, Arthur E. Weyman

Thyroid indices in panic disorder.

Scott M. Fishman, David V. Sheehan, Daniel B. Carr

Lactate infusion in anxiety research: Its evolution and practice

David V. Sheehan, Daniel B. Carr, Scott M. Fishman, M. M. Walsh, D. Peltier-Saxe

Monoamine Oxidase Inhibitors and Alprazolam in the Treatment of Panic Disorder and Agoraphobia

David V. Sheehan

Panic anxiety: a new biological model.

Daniel B. Carr, David V. Sheehan

Delineation of anxiety and phobic disorders responsive to monoamine oxidase inhibitors: implications for classification.

David V. Sheehan

Delineation of anxiety and phobic disorders responsive to monoamine oxidase inhibitors: implications for classification.

David V. Sheehan

Differentiating panic disorders from dental anxiety.

Weiner Aa, David V. Sheehan

Some Biochemical Correlates of Panic Attacks with Agoraphobia and Their Response to a New Treatment

David V. Sheehan, James H. Coleman, David J. Greenblatt, Kenneth J. Jones, Peter H. Levine, Paul J. Orsulak, Myron B. Peterson, Joseph J. Schildkraut, Eugene Uzogara, David Watkins

The classification of phobic disorders.

David V. Sheehan, Kathy Harnett Sheehan

Panic attacks and the dexamethasone suppression test.

David V. Sheehan, Claycomb Jb, Owen S. Surman, Lee Baer, James H. Coleman, Gelles L

Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias.

David V. Sheehan, Jonathan R. T. Davidson, Theo C. Manschreck, Van Wyck Fleet J

Panic disorder in genotypic HLA identical sibling pairs.

Owen S. Surman, David V. Sheehan, Fuller Tc, Gallo J

The diagnosis and drug treatment of anxiety disorders

David V. Sheehan

The classification of anxiety and hysterical states. Part II. Toward a more heuristic classification.

David V. Sheehan, Kathy Harnett Sheehan

Diagnostic classification of anxiety and phobic disorders.

David V. Sheehan, Kathy Harnett Sheehan

Current behavioral modes of reducing dental anxiety.

Weiner Aa, Moore Pa, David V. Sheehan

The classification of anxiety and hysterical states. Part I. Historical review and empirical delineation.

David V. Sheehan, Kathy Harnett Sheehan

Panic Attacks and Phobias

David V. Sheehan

Psychosocial Predictors of Accident/Error Rates in Nursing Students: A Prospective Study:

David V. Sheehan, James J. O'Donnell, Anne Fitzgerald, Linda K. Hervig, Harold W Ward

Follow-up study of hypnotherapy for smoking.

David V. Sheehan, Owen S. Surman

Age of onset of phobic disorders: A reevaluation

David V. Sheehan, Kathy E. Sheehan, William E. Minichiello

MONOAMINE OXIDASE INHIBITORS: PRESCRIPTION AND PATIENT MANAGEMENT

David V. Sheehan, J. Barry Claycomb, Nicholas Kouretas

Treatment of Endogenous Anxiety With Phobic, Hysterical, and Hypochondriacal Symptoms

David V. Sheehan, James C. Ballenger, Gary Jacobsen

The Relationship between Response Qualities of Life Change Events and Future Illness Rates

David V. Sheehan, James J. O'Donnell, Anne Fitzgerald, Linda K. Hervig, Harold W Ward

Empirical assessment of spiegel's hypnotic induction profile and eye-roll hypothesis

W. D. Latta, E. G. Regina, G. M. Smith

Influence of Psychosocial Factors on Wart Remission

Letter: Van Gogh--color blind?

Sheehan D